Mechanism of Action
ANG-3777 is an HGF mimetic engineered to bind to the c-Met receptor and activate the pathways involved in tissue repair and complement the endogenous mismatch between HGF levels and c-Met expression after organ injury.
Acute Kidney Injury after Renal Transplantation: ANG-3777 is currently in a randomized, double-blind placebo-controlled Phase 3 trial for the treatment of acute kidney injury associated with delayed graft function. Data are expected in 2020.
Acute Kidney Injury after Cardiac Surgery: A randomized, double-blind, placebo-controlled Phase 2 trial examining the efficacy of ANG-3777 in reducing acute kidney injury in 240 patients after a cardiac procedure is currently enrolling. Data are expected in 2020.